Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 31, 2005

Study Completion Date

April 30, 2007

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

PN2034

DRUG

Insulin

Trial Locations (18)

17011

Camp Hill Clinical Research Center, Camp Hill

27103

Piedmont Medical Research Associates, Winston-Salem

27609

Neem Research Group of Raleigh, Raleigh

28211

Medical Research Associates of Charlotte, Charlotte

28262

Neem Research Group of Charlotte, Charlotte

28601

Unifour Medical Research Associates, Hickory

29201

Neem Research Group, Columbia

32779

Genesis Research International, Longwood

32789

Endocrine Clinical Research, Winter Park

33021

Center for Diabetes and Endocrine Care, Hollywood

33028

Andres Patron, DO PA, Pembroke Pines

33156

Baptist Diabetes Associates, Miami

33321

CLIRECO,Inc., Tamarac

67203

PRN of Kansas, Wichita

73103

COR Clinical Research, LLC, Oklahoma City

77386

Oaks Medical Center, Spring

97504

Clinical Research Institute of Southern Oregon, PC, Medford

06708

Phoenix Internal Medicine Associates, Waterbury

All Listed Sponsors
lead

Wellstat Therapeutics

INDUSTRY

NCT00110864 - Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter